In his weekly clinical update, Dr. Griffin discusses immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age, influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults, COVID-19 surveillance after expiration of the public health emergency declaration, provisional mortality data, targeted vaccine messaging to promote COVID-19 vaccines for children and youth, vaccines and related biological products advisory committee meeting June 15, 2023 announcement, how to overhaul the CDC, impact of SARS-CoV-2 variants on inpatient clinical outcome, prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status, gut bacteria cocktail helps long COVID, and gut microbiota‐derived symbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Immunogenicity and tolerability of a bivalent norovirus vaccine in children (HVI) Influenza hemagglutinin stem nanoparticle vaccine induces neutralizing antibodies in healthy adults (STM) COVID-19 surveillance after expiration of the public health emergency declaration (CDC) Provisional mortality data (CDC) Targeted messaging to promote COVID-19 vaccines for children and youth (Pediatrics) Vaccines and biological products advisory committee meeting announcement (FDA) How to overhaul the C.D.C (NYTIMES) Impact of SARS-CoV-2 variants on inpatient clinical outcome (CID) Prevalence of post-COVID19 condition 12 weeks after Omicron infection and vaccination status (CID) Gut bacteria cocktail helps long COVID (MedPage) Gut microbiota‐derived synbiotic formula as a therapy for COVID‐19 (NIH) Contribute to our FIMRC fundraiser at PWB Letters read on TWiV 1006 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]